Iovance Biotherapeutics, Inc., a biotechnology company developing polyclonal tumor infiltrating lymphocyte (TIL) cell therapies for cancer, received approval from the U.S. FDA for AMTAGVI (lifileucel) suspension for intravenous infusion. AMTAGVI is a tumor-derived autologous T cell immunotherapy for the treatment of adults with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor...